EUCTR2004-004966-34-IT进行中（未招募）不适用
A Phase III, open-label trial to assess the non-immunogenicity and safety of Org 36286 in patients undergoing repeated controlled ovarian stimulation cycles using either a multiple dose GnRH antagonist protocol or a long protocol of GnRH agonist Protocollo 38825
ORGANON ITALIA0 个研究点目标入组 250 人开始时间: 2007年2月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above.Respiratory Syncytial Virus InfectionsMedDRA version: 21.1Level: LLTClassification code: 10035692Term: Pneumonia due to respiratory syncytial virus Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10061603Term: Respiratory syncytial virus infection Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10066741Term: Respiratory syncytial virus infection recurrent Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10035732Term: Pneumonia respiratory syncytial viral Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10052200Term: Respiratory syncytial virus infection NOS Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10038718Term: Respiratory syncytial virus bronchiolitis Class: 100000004862MedDRA version: 21.1Level: LLTClassification code: 10067384Term: Respiratory syncytial virus pneumonitis Class: 10021881MedDRA version: 21.1Level: PTClassification code: 10069811Term: Respiratory syncytial virus bronchitis Class: 100000004862CTIS2023-510190-34-00GlaxoSmithKline Biologicals1,450
进行中（未招募）
1 期
A study to assess the usefulness of fluciclovine (18F) PET/CT in patients with rising PSA after treatment of prostate cancerProstate cancer with biochemical recurrence after radical treatmentMedDRA version: 20.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000625-37-GBBlue Earth Diagnostics Limited180
进行中（未招募）
不适用
A randomized, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer - AVEX: Avastin in Elderly with XelodaEUCTR2006-003293-10-GRF. Hoffmann-La Roche Ltd.430
进行中（未招募）
不适用
A randomized, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer - AVEX: Avastin in Elderly with XelodaFirst line metastatic colorectal carcinomaMedDRA version: 8.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2006-003293-10-SIF. Hoffmann-La Roche Ltd.430
进行中（未招募）
不适用
A randomized, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer - AVEX: AVastin in the Elderly with XelodaFirst line metastatic colorectal carcinomaMedDRA version: 8.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2006-003293-10-ATF. Hoffmann-La Roche Ltd.280